News | Patient Positioning Radiation Therapy | August 15, 2019

Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality

Maastro Proton Therapy center will deploy C-RAD Catalyst PT patient positioning system with Mevion S250i proton therapy system

Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality

Catalyst PT image courtesy of C-RAD

August 15, 2019 — Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton therapy system. The union of both products supports a seamless workflow with uninterrupted patient surface tracking and monitoring from setup through treatment.

C-RAD offers a specific version of its Catalyst System for use in proton and particle therapy - the Catalyst PT, based on the Catalyst technology and software.

Maastro Proton Therapy (Maastricht, The Netherlands), equipped with the Mevion 250i Proton Therapy System, and C-RAD announced a strategic agreement in 2018 to install the Catalyst PT at the center. C-RAD and Mevion co-developed a solution based on both companies’ products that allows a high level of integration to enhance user comfort and patient safety.

Guided by the expertise and requirements of Maastro Proton Therapy, the two industry partners focused on developing the interface required to support a seamless workflow, including automatic patient position correction and monitoring throughout the entire treatment process.

The installation of the Catalyst PT at Maastro Proton Therapy was commissioned over the past month and has been released for clinical operation beginning this August. The center will be deploying the Catalyst PT especially for thoracic tumor indications treated on the Mevion system.

Geert Bosmans, managing director of Maastro Proton Therapy said, “To provide our patients with an improved high-quality treatment plan we installed the C-RAD surface tracking system in our center. We will use it to accurately position and continuously monitor our patients during treatment for increased high-precision radiation therapy.”

The Catalyst PT system is now available to current and future Mevion customers.

For more information: www.mevion.com, www.c-rad.com

Related Content

Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population

Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population. Chart courtesy of the American Cancer Society

News | Radiation Oncology | January 13, 2020
January 13, 2020 — The cancer death rate declined
Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital.

Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital. Image courtesy of Saarland University/Thorsten Mohr

 

News | Prostate Cancer | January 13, 2020
January 13, 2020 — When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewha
Lung cancer patients who are inactive prior to chemoradiation are less likely to tolerate treatment and more likely to see their cancer return
News | Lung Cancer | January 08, 2020
January 8, 2020 — Numerous ...
Six of the top 20 radiotherapy stories in 2019 involved proton therapy. This includes two video inetrviews shot during a site visit to the Northwestern Medicine Proton Center in the Chicago suburb of Warrenville, Ill.

Six of the top 20 radiotherapy stories in 2019 involved proton therapy. This includes two video inetrviews shot during a site visit to the Northwestern Medicine Proton Center in the Chicago suburb of Warrenville, Ill.

Feature | Radiation Oncology | January 03, 2020 | Dave Fornell, Editor
January 3, 2020 — Here is the top 20 pieces of radiation oncology content on the Imaging Technology News (ITN) websit
Artificial intelligence was by far the hottest topic in both radiology and radiation oncology in 2019, and AI is the subject of 8 of the top 2019 ITN videos. This image is a prostate treatment plan created autonomously by an AI algorithm from RaySearch and is the subject of the No. 2 video on the list. Deep learning in radiology and radiation oncology.

Artificial intelligence was by far the hottest topic in both radiology and radiation oncology in 2019, and AI is the subject of 8 of the top 2019 ITN videos. This image is a prostate treatment plan created autonomously by a machine learning algorithm from RaySearch and is the subject of the No. 2 video on the list. 

Feature | December 30, 2019
Here are the top 20 best performing videos posted on the Imaging Technology News website (ITN) from the past year, ba
Ferrotran (formerly Combidex), based on Ferumoxtran-10, is the only contrast agent which can detect lymph node metastases as small as 2 mm diameter

Ferrotran (formerly Combidex), based on Ferumoxtran-10, is the only contrast agent which can detect lymph node metastases as small as 2 mm diameter. Standard MRI or CT are not able to detect lymph node metastases smaller than 7 – 8 mm. Since most of the oncologic patients are dying due to metastases, a precise diagnostic is of utmost importance. The detection of small metastases, combined with the very clear and contrast rich MRI image of Ferrotran, enables an earlier and more precise treatment. Therefore, Ferrotran gives the patient a much higher chance of recovery.

News | Prostate Cancer | December 24, 2019
December 24, 2019 — SPL Medical announced today that the first patient has been successfully diagnosed with suspected
Beamscan MR for ViewRay MRIdian and for Elekta Unity

Beamscan MR for ViewRay MRIdian and for Elekta Unity

News | Radiation Therapy | December 23, 2019
December 23, 2019 — The Beamscan MR motorized 3-D...